Johnson & Johnson (BIT:1JNJ)
Italy · Delayed Price · Currency is EUR | Market Cap | 541.90B +51.1% |
| Revenue (ttm) | 85.86B +8.1% |
| Net Income | 18.45B -7.2% |
| EPS | 7.56 -7.6% |
| Shares Out | n/a |
| PE Ratio | 29.38 |
| Forward PE | 22.26 |
| Dividend | 4.50 (2.00%) |
| Ex-Dividend Date | May 25, 2026 |
| Volume | 686 |
| Open | 227.75 |
| Previous Close | 226.50 |
| Day's Range | 224.80 - 227.75 |
| 52-Week Range | 145.00 - 241.55 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 13, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, 2026. Management will partici...
Jim Cramer highlights 5 investing themes — and the stocks to buy for each
CNBC's Jim Cramer said earnings season reinforced five investing themes he thinks will produce the market's best buying opportunities. He highlighted stocks to buy for each theme, including Capital On...
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9th, 2026. Management will participate in a Fires...
Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medi...
Johnson & Johnson Transcript: Investor update
OTTAVA launches as a table-integrated robotic surgery platform, targeting expansion in the U.S. and globally with a differentiated design, automation, and digital ecosystem. Early clinical results show strong workflow and efficiency benefits, with a roadmap for rapid indication and instrument expansion.
Inside J&J's Lab to Create a Simpler Robotic Surgery Device
After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race...
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients...
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary...
Johnson & Johnson lowers 2026 profit forecast
Johnson & Johnson cut 2026 profit forecast on Wednesday, citing the combined financial impact of its newly completed acquisition of Firefly Bio and a strategic partnership with Sail Biomedici...
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CA...
Explainer: Can J&J finally put the talc litigation behind it?
After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that cou...
Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer
Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer.
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits
Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.
Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit
Landmark deal covers about 76,000 claims and could end contentious, decade-long legal battle
J&J offers $5.5bn to settle baby powder lawsuits
Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer.
Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits
The drugmaker aims to put an end to litigation that has been going on for more than a decade.
Johnson & Johnson announces $5.5 billion settlement of talc lawsuits
Johnson & Johnson said on Monday it has reached a $5.5 billion settlement that will resolve tens of thousands of lawsuits alleging its baby powder and other talc products cause ovarian cancer.
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the "Company") today announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation wit...
Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios
Robert Kiyosaki's warning that the world faces what he called the “greatest depression in world history” does not seem to be a Wall Street consensus forecast. Yet, the Rich Dad Poor Dad author and a l...
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluat...
US judge casts doubt on 69,000 cases alleging J&J talc caused cancer
A federal judge cast doubt on Wednesday on claims by approximately 69,000 people alleging that Johnson & Johnson's baby powder and other talc products caused ovarian cancer, saying plaintiffs must pr...
Johnson & Johnson's robotic surgery device gets US FDA marketing authorization
Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery device, clearing the way for the healthcare conglomerate to ...
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, the ...